Plain-English translation of NCT04861051 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers at Stanford are studying how —a medication commonly used in hospitals—affects the brains of people with epilepsy. The study will give you one dose of the medication and use special EEG electrodes (already placed as part of your regular epilepsy care) to record what happens in your brain. This will help doctors understand how this medication works and whether it might be useful for epilepsy treatment.
can cause a temporary feeling of disconnection from your body or surroundings called dissociation. Doctors don't fully understand why this happens or how it relates to epilepsy. This study aims to fill that gap so they can better predict side effects and potentially develop safer treatments.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous dose of the medication while you're already in the epilepsy monitoring unit with EEG electrodes attached. Researchers will monitor your brain activity during and after the infusion to observe and record how the medication affects your brain. The study involves this one treatment session, with monitoring happening as part of your existing care at the unit.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States
Safety & dosing
Sponsor
Stanford University
Enrollment target
~20 participants
Started
July 2021
Primary completion
August 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Arjay Cordero
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.